cyrilzakka/clinical-trials huggingface dataset:
Comparison of Sciatic Nerve Gliding and Lower Extremity Dynamic Stretch on Hamstring Flexibility of Athletes

In this research, the main purpose is to determine the comparison of acute effect of sciatic nerve gliding and lower extremity dynamic stretching exercises on hamstring flexibility and athletic performance. The participants will be begin with warm-up sessions for 3-5 minutes then baseline data (pre-test): hamstring flexibility will be measured. The order of pre-test will be randomized and same order will be used for post-test. This is a community service addition, added so that everyone in the society can get to know the effects of nerve gliding and lower extremity dynamic stretches on hamstring flexibility, will be cost effective, and will reduce their visits to the therapist.

Randomized controlled trial with 1 month follow-up. The sample size is 40. subjects will be divided in two groups, 20 athletes will be given a session of sciatic nerve gliding while lower extremity stretch will be given to remaining 20 athletes. Study duration is of 6 months.Sampling technique employed will be convenient with random assignment. Individuals of age group 18-40 years having male gender regularly exercise at least once a week for 30 minutes. Tools used in the study are Universal inclinometer and Active knee extension test and SLR TEST. Data will be analyzed through IBM SPSS 23


Eligibility Criteria:
Inclusion Criteria:

* 18 to 40 year
* Footballers players
* Male gender
* Hamstring tightness of one or both legs,
* Unable to achieve greater than 160 degree of knee extension with hip at 90 degree of flexion
* Able to reach \<70 degree hip flexion in SLR

Exclusion Criteria:

* Individuals who had sustained injury in the prior six months to the lumbar region,
* Limited activity level for more than 3 days,
* Low back problems (disc bulge etc.)
* Individual with a history of fracture or trauma were excluded from the study
Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19

This is a phase 2 study in which subjects with coronavirus disease 2019 (COVID-19) will receive VIR-7831 (Sotrovimab) Generation 1 (Gen1) or VIR-7831 (Sotrovimab) Generation 2 (Gen2) and will be assessed for safety, tolerability, and pharmacokinetics.


Eligibility Criteria:
Inclusion Criteria:

* For Part A, participants must be aged 18 years or older at the time of obtaining informed consent
* For Parts B and C, participants must be aged between 18 years and 69 years old at the time of obtaining informed consent
* Participants who have a positive SARS-CoV-2 test result ≤7 days prior to enrollment and oxygen saturation ≥94% on room air and have COVID-19 symptoms and ≤7 days from onset of symptoms

Exclusion Criteria:

* Currently hospitalized or judged by the investigator as likely to require hospitalization in the next 24 hours
* Symptoms consistent with severe COVID-19
* Participants who, in the judgement of the investigator are likely to die in the next 7 days.
* Severely immunocompromised participants
* For Parts A and B, prior receipt of a SARS-CoV-2 vaccine at any time prior to enrollment (vaccination with an authorized or approved SARS-CoV-2 vaccine will not be allowed for 90 days after dosing)
* For Parts B and C, conditions that would prohibit receipt of IM injections in the investigator's opinion
* For Parts A, B and C, receipt of any vaccine within 48 hours prior to enrollment (vaccination with an authorized or approved SARS-CoV-2 vaccine will not be allowed for 90 days after dosing)
Mapping Multidimensional Illness Trajectories of Patients With End-stage Kidney Disease

Patients with end-stage kidney disease (ESKD) must manage not only the demands of dialysis and comorbid conditions but also associated symptoms and acute life-threatening events that contribute to functional limitations and increased risk of mortality. Yet little is known about the trajectories of quality of life dimensions in patients with ESKD when they experience acute life-threatening episodes, to guide palliative care for this population. In this prospective, descriptive study, we will identify trajectories of symptoms, physical functioning, psychosocial needs, and emotional and spiritual well-being in 200 patients with ESKD who are at a high risk of experiencing acute life-threatening events and mortality within 12 months.


Eligibility Criteria:
Inclusion Criteria:

* aged 18 years or older;
* receiving either Hemodialysis or Peritoneal dialysis
* on dialysis either \< 3 months or ≥ 6 months with a Charlson Comorbidity Index (CCI) score ≥ 5

Exclusion Criteria:

* Patients who are enrolled in hospice or too sick to participate in questionnaire completion will not be eligible.
* Kidney transplant candidates will be excluded because their illness trajectories after transplant are likely to differ.
Transcranial Infrared Laser Stimulation (TILS) of Prefrontal Cognition in Post-traumatic Stress Disorder (PTSD)

This study evaluates the effects of transcranial infrared laser stimulation (TILS) on prefrontal metabolism and hemodynamics in veterans with post-traumatic stress disorder (PTSD). The subjects will receive six TILS interventions and one sham intervention in a course of seven weeks.

Post-traumatic stress disorder (PTSD) is often associated with cognitive impairments. It has been indicated that hypoactivity of the prefrontal cortex plays a major role in the disrupted neural circuitry of mood and cognition.

Transcranial infrared laser stimulation (TILS) is a neural type of photobiomodulation that can elevate neuronal metabolism by exciting cytochrome c oxidase (CCO). Veterans with PTSD will receive prefrontal TILS interventions once-per-week for six weeks. They will also receive an additional sham intervention (laser power = 0) that will be randomly assigned into the first two sessions. Broadband near-infrared spectroscopy (bbNIRS) will be used to directly assess the CCO changes during every TILS/sham session.

Veterans' prefrontal functions will be evaluated with short-term memory tasks before and after each intervention. The prefrontal activities will also be imaged by functional near-infrared spectroscopy (fNIRS) to objectively assess the functional changes due to TILS/sham interventions.

Eligibility Criteria:
Inclusion Criteria:

* War-zone and non-war-zone veterans
* Ages 18-60 years old
* Males and females
* Able to read, speak, and understand English
* Medical records showing prior diagnosis of PTSD (here it refers to the records prior to TILS, which will be assessed and obtained in Visit 1)
* Medical records showing diagnosis of PTSD (here it refers to the CAPS-5 record prior to TILS, which will be assessed and obtained in Visit 1)
* On stable doses of any psychotropic medications for at least 4 weeks

Exclusion Criteria:

* Significant physical disability to perform a computerized memory task
* Past/current significant medical/neurological/mental health disorders known to affect cognitive functioning (e.g., stroke, dementia, schizophrenia, AIDS)
* Presence of moderate/severe TBI, defined as having: alteration of consciousness/mental state \>24 hours; posttraumatic amnesia \>1 day; loss of consciousness \>30 minutes; and/or abnormal structural neuroimaging. We will not exclude veterans with mild TBI, which is found in nearly 50% of veterans with PTSD
* Alcohol abuse/dependence for the past 12- months, as determined by the Rapid Alcohol Problems Screen score \>0
* Drug abuse/dependence for the past 12- months, as determined by the Drug Abuse Screening Test-10 score \>2
* Severe depression (PHQ-9 total score \>19), significant risk of suicide (SBQ-R \>6), severe headache (PHQ-15, Item e =2), and/or severe dizziness (PHQ-15, Item g =2)
* Opiate use in the month prior to study entry
Probiotics Effect on Glucose and Lipid Metabolism and Gut Microbiota in Patients With Obesity

The purpose of this study is to determine whether the probiotics will be effective in the treatment of obesity

This study aims to evaluate the effect of probiotics on the improvement of glucose and lipid metabolism, as well as the gut microbiota.Baseline, 1 month and 3 months data will be collected and put into analysis to provide some suggestions on the probiotics use in the clinical practice for obesity patients.

Eligibility Criteria:
Inclusion Criteria:

1. Age 15-60 years
2. BMI≥28.0kg/m2
3. Agree to cooperate in the trial
4. Provision of written informed consent

Exclusion Criteria:

1. With chronic gastrointestinal diseases, severe immune deficiency, lactose intolerance
2. Diabetes
3. Use antibiotics, bacteriostatic agents (eg berberine), lipid-lowering drugs, antacids, H2 Blockers, proton pump inhibitors, corticosteroids or sex hormones
4. Use any probiotics in the last 3 months
5. Allergic constitution
6. Participating in any other clinical trials
7. Was not able to insist until the end
8. Pregnant and lactating women
An Open-Label, Uncontrolled Clinical Trial of Oral 566C80 for the Treatment of Patients With Severe PCP Who Are Intolerant and/or Unresponsive to Therapy With Trimethoprim/Sulfamethoxazole and Parenteral Pentamidine

To facilitate provision of atovaquone (566C80) to patients who have severe Pneumocystis carinii pneumonia (PCP) and are intolerant and/or unresponsive to trimethoprim / sulfamethoxazole ( TMX / SMX ); to monitor serious adverse events attributable to 566C80.


Eligibility Criteria:
Inclusion Criteria

Patients must have the following:

* Clinical diagnosis of acute severe Pneumocystis carinii pneumonia (PCP).
* Dose-limiting intolerance to TMP / SMX and parenteral pentamidine.
* Willingness and ability to give informed consent.

Exclusion Criteria

Co-existing Condition:

Excluded:

* Patients with a history of intolerance to 566C80. Patients with the following prior conditions are excluded: History of serious dose-limiting adverse experience during previous 566C80 therapy, thought to be attributable to the drug.

Required:

* Trimethoprim / sulfamethoxazole (TMP/SMX); pentamidine.
Mouth Odor on Preventing Pneumonia by Oral Frailty

This research plan aims to first collect data on the oral function and oral hygiene status of the elderly population in the community and to understand the normal model of oral frailty among the older adults in the community. Subsequently, a comparison will be made between the oral status of hospitalized patients and the community-dwelling elderly population. The goal is to verify whether oral odor can be used as an objective biological indicator following intervention.

The first stage will aim to examine the relationships between the level of oral frailty and pneumonia-associated pathogens, as well as to establish a mouth odor database among community-dwelling people; The second stage will compare the differences of the level of oral frailty, pneumonia associated pathogens, and mouth odor between 144 middle-aged and older healthy people and 160 hospitalization patients. The third stage will confirm whether the mouth odor is an effective biological maker to show the changes of oral frailty, pneumonia-associated pathogens, and mouth odor after oral management rehabilitation.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 50 years old,
* Alert and oriented,
* With sufficient comprehension and cooperation,
* Willing to participate in oral assessment.

Exclusion Criteria:

* Patients who score below 5 on the General Practitioner Assessment of Cognition (GPCOG),
* Patients with oral treatments such as oral cancer treatment,
* Patients with oral treatments such as periodontal disease treatment.
Breast Cancer and Breast Self-examination Education

According to a news published by the World Health Organization (WHO); More than 2.3 million cases of breast cancer occur each year, making it the most common cancer among adults. In 95% of all countries, breast cancer is the first or second cause of female cancer death. In 2020, 2.3 million women worldwide were diagnosed with breast cancer and 685,000 deaths occurred. In Turkey, breast cancer ranks first among the most common cancer types in women, and the number of breast cancer cases in women in 2020 was recorded as 74 638. As a result of this situation, WHO (2023) published the Global Breast Cancer Initiative Framework to save 2.5 million lives from breast cancer by 2040. This published framework includes health promotion for early detection, timely diagnosis and comprehensive management of breast cancer.

One of the most effective ways to reduce breast cancer mortality and morbidity rate is early diagnosis. It is important to determine early diagnosis and signs and symptoms of cancer before they appear. Early diagnosis of breast cancer is possible with breast self-examination (BSE), clinical breast examination and mammography. Breast self-examination is an important examination method in terms of detecting changes in breast tissue and preventing subsequent complications. It is also an easy-to-apply, cheap and non-invasive method. In Turkey, it is recommended that women regularly perform breast self-examination every month after the age of 20, women between the ages of 20 and 40 should have a clinical breast examination every two years, and women between the ages of 40 and 69 should have a clinical breast examination every year and have a mammogram every two years.

There are studies showing that fear of breast cancer has a positive and negative impact on early diagnosis behaviors. Champion et al. (2004) stated that women with moderate breast cancer fear had a high rate of early detection behavior, whereas low and high fear levels had a negative effect on behavior. In the study conducted by Yavan et al. (2010) on 188 women, 2% of the women. They found that 3 of them had regular BSE and 78.7% of them had never had a mammography. In addition, 85% of the women included in the study stated that they had a fear of breast cancer due to a family history of breast cancer, being diagnosed with breast cancer, and the presence of risk factors. Study results show that fear of breast cancer affects screening results. Therefore, aim in the study is; To determine the effect of breast cancer and BSE training given to women on breast cancer fear and BSE skills.


Eligibility Criteria:
Inclusion Criteria:

* Able to read and write,
* Having no history of breast cancer,
* No communication barriers,
* Not pregnant or lactating,
* Those who are willing and agree to participate in the research.

Exclusion Criteria:

* Having a mental illness,
* Those who wish to withdraw from any part of the research.
Placement of CS/LV Pacing Leads With EnSite NavX Guidance

This study utilizes the 3D mapping capabilities of the EnSite NavX mapping system to help guide the placement of the left ventricular lead during cardiovascular resynchronization therapy implant procedures with the goal of reducing fluoroscopic exposure and procedure time.


Eligibility Criteria:
Inclusion Criteria:

* Patients schedule to undergo CRT implant (per established guidelines)

Exclusion Criteria:

* Standard exclusions to CRT implant procedures
Study of the Correlation Between Preoperative Precise Biometrics, Spatial Assessment and Postoperative Visual Quality in Cataract Patients

This study summarizes the experience of precision treatment and postoperative management of various types of cataract, and intend to further improve the quality of Clinical Cataract diagnosis and treatment.

Based on the existing cataract surgery methods, through prospective follow-up study, this study summarizes the experience of precision treatment and postoperative management of various types of cataract, and intends to further improve the quality of Clinical Cataract diagnosis and treatment.

Eligibility Criteria:
Inclusion Criteria:

* Patients with monocular or binocular cataract, lens opacity or abnormal position, need surgery

Exclusion Criteria:

* The history of systemic diseases and medication affecting vision, diabetic patients with systemic conditions complicated with retinopathy, uncontrolled blood glucose, severe eye diseases, eye trauma, eye surgery, severe dry eye and ocular surface diseases, strabismus and amblyopia were identified
Influence of Aliskiren on Proteinuria

To evaluate the proteinuria lowering efficacy as well as tolerability and safety of the renin inhibitor aliskiren compared with that of placebo and angiotensin converting enzyme inhibitor perindopril in patients with non-diabetic chronic renal disease.

Proteinuria is a major risk factor for progression to end-stage renal disease in both diabetic and nondiabetic nephropathies. Angiotensin II and aldosterone are the key players in the development of renal failure, either directly by promoting tissue fibrosis or indirectly through their action on glomerular hemodynamic and proteinuria. Therefore, pharmacological inhibition of the renin-angiotensin-aldosterone system (RAAS) may have a beneficial impact on proteinuria and chronic kidney diseases progression. Recently, renin inhibitors, a new class of drugs that selectively inhibits angiotensin II formation at the first step of the RAAS cascade has been introduced to clinical practice. Aliskiren is the first orally bioavailable direct renin inhibitor approved for the treatment of hypertension. Blood pressure (BP)-lowering effect of aliskiren is associated with a decreased generation of angiotensin I, as it blocks its generation from angiotensinogen, by inhibiting the active enzymatic site of renin. The investigators plan this study to evaluate the short-term effects of treatment with aliskiren to those of placebo and ACEI perindopril on proteinuria.

Eligibility Criteria:
Inclusion Criteria:

* age 18-65 years
* chronic non-diabetic proteinuric nephropathy
* creatinine clearance above 30 ml/min
* stable proteinuria above 500 mg/ 24 hours
* blood pressure above 125/75 mmHg and below 150/95 mmHg
* no steroids or other immunosuppressive treatment for a minimum of six months before the study

Exclusion Criteria:

* unstable coronary heart disease
* decompensated congestive heart failure in the previous 6 months
* episode of malignant hypertension or stroke in the history
* diabetes
* creatinine clearance below 30 ml/min
Quality Control of CE-Certified Phonak Hearing Aids - 2020_06

Phonak Hearing Devices pass through different development and study phases. At an early stage, feasibility studies are conducted to investigate new algorithms, features and functions in an isolated manner. If the benefit is proven, their performance is then investigated regarding interdependency between all available algorithms, features and functions running in parallel in a hearing aid (pivotal/pre-validation studies) and, resulting from the pre-validation studies, they get optimized. Prior to product launch, the Phonak Hearing Systems get reviewed by a final quality control in terms of clinical trials. This is a validation study, investigating improved algorithms, features, functions and wearing comfort. This will be a clinical investigation which will be conducted mono centric at Sonova AG Headquarters based in Stäfa (Switzerland).

This study will investigate the combination of the features to determine if the audiological performance and quality of the new successor of the Marvel family shows an improved benefit over Phonak Audéo Marvel before going into the System Validation. Therefore this study will be a comparative study. The study will determine if hearing impaired users wearing the successor hearing aids, have better initial acceptance with the new precalculation, better sound quality and speech intelligibility, more clarity and loudness comfort in soft and loud environments compared to Phonak Marvel RIC (Receiver in channel) hearing aids. Another objective of the study is to compare the listening effort with the two different study devices.

Eligibility Criteria:
Inclusion Criteria:

* Self-reported confidence to using Bluetooth smartphone
* Hearing Loss range: moderate and moderate/ severe
* experienced hearing aid user
* willingness and interest in testing new features
* willingness to wear behind the ear hearing aids
* Informed Consent as documented by signature

Exclusion Criteria:

* the audiogram is not in the fitting range of the intended hearing aid
* limited mobility and not in the position to attend weekly appointments in Stäfa (Switzerland)
* participant is not able to describe experiences and hearing impressions
* participant has finger movement disorders
Aquatic Power Training

Knee Osteoarthritis (OA) accounts for a significant proportion of mobility limitations and is one of the most disabling problems facing the growing population of older adults. The purpose of this research is to reduce disablement of older adults with symptomatic knee osteoarthritis.

Aquatic based training can offer many of the same benefits associated with a land based exercises but water has certain properties that provide a more gentle and welcoming environment for exercising. Buoyancy in water counteracts gravity to support the weight of the subject and decrease the forces put on the joints. Viscosity of water can provide resistance proportional to the effort exerted and with gentle friction enhancing proprioceptive feedback. Immersing in warm water can cause an increase in body temperature due to specific heat and thermal conductivity, which can cause blood vessels to dilate. In addition, hydrostatic forces reduce edema, increasing venous return and healthy circulation. \[Prins, 1999\]; \[Wilder, 1998\]

Studies have shown that water based exercise has been proven to significantly decrease pain in people with knee osteoarthritis compared to those in a land based exercise program. \[Silva, 2003\] In comparing an aquatic physical therapy session to a no intervention group the aquatic program resulted in less pain, improved physical function, quality of life, and strength. \[Hinman, 2007\]

The purpose of this research study is to determine whether an aquatic therapy program aimed at increasing muscle power will be effective in improving knee symptoms and mobility in men and women with symptomatic knee osteoarthritis.

The purpose of this study is to assess the efficacy of aquatic power training for improving mobility limitations, disability and quality of life in older adults with symptomatic knee OA.

Hypothesis 1: In older adults with symptomatic knee OA, a 6-week aquatic power training intervention will reduce lower limb mobility limitations (400m walk time).

Hypothesis 2: In comparison to baseline measures, at 6-week follow-up, there will be improvements in a) lower limb function (LLFDI), b) quality of life (KOOS Knee QOL),c) knee OA specific pain (KOOS pain) scores, and d) vastus lateralis muscle bulk (thigh muscle). These changes will be sustained at 12 week follow-up.

Eligibility Criteria:
Inclusion Criteria:

* Age 50 or older
* Symptomatic knee osteoarthritis (knee osteoarthritis diagnosed by the American College of Rheumatology criteria and frequent knee symptoms)

Exclusion Criteria:

* bilateral knee replacement
* acute or terminal illness
* unstable cardiovascular condition or other medical conditions that may impair ability to participate such as pulmonary disease requiring use of supplement oxygen, or lower limb musculoskeletal surgery in the past 6 months
* unwilling to be in a pool (approximately 4 feet deep)
* 400m walk time equal to or slower than the median for sex and decade:

M 50's 250.2 60's 289.9 70's+ 290.8

F 50's 315.9 60's 305.2 70's+ 292.5